Jump to main content
Topic: Government Payers
-
Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection
Read More
-
List Price, Net Price, and the Rebate Caught in the Middle
Read More
-
DPL Responds to HHS RFI for IPI Drug Pricing Model (Nov. 30, 2018)
Read More
-
Impact of President Trump’s Proposed 340B Hospital Eligibility Threshold
Read More
-
Does the 6% in Medicare Part B Drug Reimbursement Affect Prescribing?
Read More
-
Association of Rebates in Part D with Patient OOP and Federal Spending
Read More
-
The U.S. Government Should Buy Gilead for $156Bn to Save Money on Hep C
Read More
-
Part B Pilot Congressional Concerns
Read More
-
Part B Payment for Medicare Drugs
Read More
-
Overspending Driven by Oversized Single Dose Vials of Cancer Drugs
Read More